About Corium International (NASDAQ:CORI)
Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer's disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch.
Industry, Sector and Symbol
Trailing P/E Ratio-7.31640938981399
Forward P/E Ratio-7.86
Sales & Book Value
Annual Sales$31.86 million
Price / Sales13.11
Price / CashN/A
Book Value$0.45 per share
Price / Book25.69
Return on Equity-403.15%
Return on Assets-62.88%
Corium International (NASDAQ:CORI) Frequently Asked Questions
What is Corium International's stock symbol?
Corium International trades on the NASDAQ under the ticker symbol "CORI."
How were Corium International's earnings last quarter?
Corium International Inc (NASDAQ:CORI) released its quarterly earnings data on Thursday, February, 8th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.06. The biopharmaceutical company earned $9.32 million during the quarter, compared to analyst estimates of $7.48 million. Corium International had a negative net margin of 148.07% and a negative return on equity of 403.15%. View Corium International's Earnings History.
Where is Corium International's stock going? Where will Corium International's stock price be in 2018?
6 equities research analysts have issued twelve-month price targets for Corium International's shares. Their forecasts range from $10.00 to $14.00. On average, they expect Corium International's share price to reach $13.00 in the next twelve months. View Analyst Ratings for Corium International.
What are Wall Street analysts saying about Corium International stock?
Here are some recent quotes from research analysts about Corium International stock:
- 1. According to Zacks Investment Research, "Corium International, Inc. is a commercial-stage biopharmaceutical company. It is focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage advanced technologies in transdermal and transmucosal delivery systems. Corium has developed six marketed products in the prescription drug and consumer markets: Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain and four Crest Advanced Seal Whitestrips products. The company has two proprietary transdermal technology platforms with applications in multiple drug categories and indications: Corplex(TM) and MicroCor(R). Corium International, Inc. is headquartered in Menlo Park, California. " (1/22/2018)
- 2. Cantor Fitzgerald analysts commented, "Changes to the CORI model. We updated our CORI model Twirla segment to reflect changes made to AGRX, shifting our assumed Twirla launch to 2Q19 and increasing our pTS to 50% from 75%. We are maintaining our peak Twirla sales assumptions of $230 million in 2024. We have always assumed CORI captures a lower margin on Twirla sales in keeping with their manufacturing role that reduces the incremental value of the program relative to other proprietary projects. These changes did not alter our price target of $14." (12/22/2017)
Who are some of Corium International's key competitors?
Some companies that are related to Corium International include Prometic Life Scie (PFSCF), Karyopharm Therapeutics (KPTI), Vanda Pharmaceuticals (VNDA), MiMedx Group (MDXG), Urogen Pharma (URGN), Dova Pharmaceuticals (DOVA), Anika Therapeutics (ANIK), Aduro BioTech (ADRO), Coherus Biosciences (CHRS), CymaBay Therapeutics (CBAY), Deciphera Pharmaceuticals (DCPH), Abeona Therapeutics (ABEO), Rocket Pharmaceuticals (RCKT), Adamas Pharmaceuticals (ADMS), Novavax (NVAX), Voyager Therapeutics (VYGR), Inflarx (IFRX) and Dicerna Pharmaceuticals (DRNA).
Who are Corium International's key executives?
Corium International's management team includes the folowing people:
- David L. Greenwood, Chairman of the Board (Age 64)
- Peter D. Staple, President, Chief Executive Officer, Director (Age 65)
- Robert S. Breuil, Chief Financial Officer (Age 51)
- Parminder Singh Ph.D., Chief Technology Officer, Vice President - Research & Development (Age 52)
- Joseph J. Sarret M.D. J.D., Chief Business Officer (Age 48)
- Robert W. Thomas, Lead Independent Director (Age 54)
- Eric H. Bjerkholt, Independent Director (Age 57)
- Bhaskar Chaudhuri Ph.D., Independent Director (Age 62)
- Ronald W. Eastman, Independent Director
- Phyllis I. Gardner M.D., Independent Director (Age 65)
Who owns Corium International stock?
Corium International's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Broadfin Capital LLC (9.50%), AWM Investment Company Inc. (6.28%),
RIDGEBACK CAPITAL INVESTMENTS L.P.
(5.20%), RTW Investments LP (4.71%), BlackRock Inc. (4.65%) and Opaleye Management Inc. (2.93%). Company insiders that own Corium International stock include David Greenwood, Eric Bjerkholt, Healthcare Master Fun Broadfin, Joseph J Sarret, Life Sciences Maste Perceptive, Parminder Singh, Perceptive Advisors Llc and Timothy D Sweemer. View Institutional Ownership Trends for Corium International.
Who sold Corium International stock? Who is selling Corium International stock?
Corium International's stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Needham Investment Management LLC, Essex Investment Management Co. LLC, Royce & Associates LP, Iguana Healthcare Management LLC, AWM Investment Company Inc., EAM Investors LLC and TIAA CREF Investment Management LLC. Company insiders that have sold Corium International company stock in the last year include Healthcare Master Fun Broadfin, Joseph J Sarret, Parminder Singh and Timothy D Sweemer. View Insider Buying and Selling for Corium International.
Who bought Corium International stock? Who is buying Corium International stock?
Corium International's stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Emory University, Opaleye Management Inc., Millennium Management LLC, Candriam Luxembourg S.C.A., Tamarack Advisers LP, Two Sigma Investments LP and Two Sigma Advisers LP. Company insiders that have bought Corium International stock in the last two years include David Greenwood, Eric Bjerkholt, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Insider Buying and Selling for Corium International.
How do I buy Corium International stock?
Shares of Corium International can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corium International's stock price today?
One share of Corium International stock can currently be purchased for approximately $11.56.
How big of a company is Corium International?
Corium International has a market capitalization of $405.31 million and generates $31.86 million in revenue each year. The biopharmaceutical company earns $-47,790,000.00 in net income (profit) each year or ($1.58) on an earnings per share basis. Corium International employs 213 workers across the globe.
How can I contact Corium International?
Corium International's mailing address is 235 CONSTITUTION DRIVE, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-298-8255 or via email at [email protected]
MarketBeat Community Rating for Corium International (CORI)MarketBeat's community ratings are surveys of what our community members think about Corium International and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Corium International (NASDAQ:CORI) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||3.00||3.00||3.00||3.00|
|Ratings Breakdown: ||0 Sell Rating(s)|
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$13.00||$13.00||$13.17||$12.83|
|Price Target Upside: ||12.46% upside||8.70% upside||15.19% upside||29.50% upside|
Corium International (NASDAQ:CORI) Consensus Price Target History
Corium International (NASDAQ:CORI) Analyst Ratings History
(Data available from 3/17/2016 forward)
Corium International (NASDAQ:CORI) Earnings History and Estimates Chart
Corium International (NASDAQ CORI) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/8/2018||Q1 2018||($0.43)||($0.37)||$7.48 million||$9.32 million||View||N/A|
|11/16/2017||Q4 2017||($0.43)||($0.36)||$9.57 million||$9.44 million||View||N/A|
|8/3/2017||Q3 2017||($0.30)||($0.43)||$8.71 million||$8.11 million||View||Listen|
|5/11/2017||Q2 2017||($0.37)||($0.42)||$6.05 million||$7.35 million||View||N/A|
|2/13/2017||Q1 2017||($0.42)||($0.46)||$8.07 million||$7.00 million||View||N/A|
|11/21/2016||Q4 2016||($0.39)||($0.42)||$9.08 million||$7.92 million||View||N/A|
|8/4/2016||Q3||($0.42)||($0.34)||$8.38 million||$10.61 million||View||N/A|
|5/10/2016||Q2||($0.37)||($0.47)||$8.64 million||$6.96 million||View||Listen|
|2/8/2016||Q1||($0.35)||($0.42)||$8.93 million||$7.54 million||View||N/A|
|11/12/2015||Q4||($0.45)||($0.42)||$9.47 million||$9.27 million||View||Listen|
|7/29/2015||Q3||($0.37)||($0.33)||$10.45 million||$10.60 million||View||Listen|
|5/7/2015||Q2 2015||($0.35)||($0.40)||$9.73 million||$11.29 million||View||N/A|
|2/10/2015||Q115||($0.29)||($0.37)||$10.42 million||$9.77 million||View||N/A|
|11/17/2014||Q4 2014||($0.32)||($0.51)||$10.26 million||$11.07 million||View||N/A|
|8/12/2014||Q3 2014||($0.17)||($0.28)||$12.22 million||$10.18 million||View||N/A|
|5/13/2014||Q2 2014||($0.18)||($0.24)||$10.58 million||$10.72 million||View||N/A|
Corium International (NASDAQ:CORI) Earnings Estimates
Current Year EPS Consensus Estimate: $-1.47 EPS
Next Year EPS Consensus Estimate: $-1.31 EPS
Dividend History for Corium International (NASDAQ:CORI)
No dividend announcements for this company have been tracked by MarketBeat.com
Corium International (NASDAQ CORI) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 30.80%
Institutional Ownership Percentage: 88.58%
Corium International (NASDAQ CORI) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|1/18/2018||Life Sciences Maste Perceptive||Major Shareholder||Buy||510,000||$12.54||$6,395,400.00|| |
|1/16/2018||Perceptive Advisors Llc||Major Shareholder||Buy||50,350||$11.83||$595,640.50|| |
|11/17/2017||Healthcare Master Fun Broadfin||Major Shareholder||Sell||500,000||$10.96||$5,480,000.00|| |
|11/2/2017||Healthcare Master Fun Broadfin||Major Shareholder||Sell||150,000||$11.05||$1,657,500.00|| |
|10/4/2017||Healthcare Master Fun Broadfin||Major Shareholder||Sell||218,100||$11.01||$2,401,281.00|| |
|8/22/2017||Parminder Singh||Insider||Sell||30,415||$7.59||$230,849.85||30,762|| |
|8/17/2017||Parminder Singh||Insider||Sell||32,000||$7.61||$243,520.00|| |
|8/17/2017||Timothy D. Sweemer||CAO||Sell||12,012||$7.62||$91,531.44|| |
|8/16/2017||Timothy D. Sweemer||CAO||Sell||15,488||$7.82||$121,116.16|| |
|7/20/2017||Joseph J. Sarret||Insider||Sell||2,038||$8.95||$18,240.10|| |
|6/30/2017||Life Sciences Maste Perceptive||Major Shareholder||Buy||301,004||$7.71||$2,320,740.84|| |
|5/25/2017||Perceptive Advisors Llc||Major Shareholder||Buy||1,902,400||$6.25||$11,890,000.00|| |
|5/19/2016||Eric Bjerkholt||Director||Buy||24,500||$3.64||$89,180.00|| |
|5/12/2016||David Greenwood||Director||Buy||3,000||$3.58||$10,740.00||3,000|| |
|2/25/2015||Peter D Staple||CEO||Buy||3,600||$6.99||$25,164.00|| |
|11/24/2014||Robert S Breuil||CFO||Buy||4,600||$5.38||$24,748.00|| |
|11/21/2014||Peter D Staple||CEO||Buy||9,000||$5.34||$48,060.00|| |
|8/27/2014||Peter D Staple||CEO||Buy||2,578||$6.10||$15,725.80|| |
|5/30/2014||Peter D Staple||CEO||Buy||7,200||$7.04||$50,688.00|| |
|4/8/2014||Woodlands Health Venture Essex||Major Shareholder||Buy||400,000||$8.00||$3,200,000.00|| |
Corium International (NASDAQ CORI) News Headlines
|Corium International Inc (CORI) Receives Average Recommendation of "Buy" from Brokerages|
www.americanbankingnews.com - March 17 at 5:30 PM
|$7.07 Million in Sales Expected for Corium International Inc (CORI) This Quarter|
www.americanbankingnews.com - March 15 at 1:47 PM
|Cantor Fitzgerald Comments on Corium International Inc's FY2018 Earnings (CORI)|
www.americanbankingnews.com - March 14 at 10:07 AM
|Corium International Inc (CORI) is Tamarack Advisers LP's 8th Largest Position|
www.americanbankingnews.com - March 6 at 10:30 AM
|AWM Investment Company Inc. Sells 31,557 Shares of Corium International Inc (CORI)|
www.americanbankingnews.com - March 6 at 4:44 AM
|BRIEF-RTW Investments Reports Passive Stake Of 5.29% In Corium International|
www.reuters.com - March 5 at 4:35 PM
|Corium International Inc (CORI) Stake Lessened by Royce & Associates LP|
www.americanbankingnews.com - March 5 at 11:09 AM
|Emory University Acquires New Position in Corium International Inc (CORI)|
www.americanbankingnews.com - March 4 at 3:02 PM
|Corium International Inc (CORI) is Broadfin Capital LLC's 6th Largest Position|
www.americanbankingnews.com - March 2 at 5:08 AM
|Here's Why Corium International Sank Today|
finance.yahoo.com - March 1 at 4:22 PM
|Corium Prices Offering of $100 Million of 5% Convertible Senior Notes|
finance.yahoo.com - March 1 at 9:38 AM
|Corium Announces Proposed Offering of $100 Million of Convertible Senior Notes; Receives FDA Feedback on Pilot Bioequivalence Study|
finance.yahoo.com - February 28 at 4:32 PM
|Zacks: Analysts Anticipate Corium International Inc (CORI) Will Post Quarterly Sales of $7.07 Million|
www.americanbankingnews.com - February 26 at 5:52 AM
|Zacks: Brokerages Anticipate Corium International Inc (CORI) Will Post Earnings of -$0.41 Per Share|
www.americanbankingnews.com - February 24 at 8:06 AM
|Corium International Inc (CORI) Given Average Rating of "Buy" by Brokerages|
www.americanbankingnews.com - February 20 at 5:32 PM
|FY2018 EPS Estimates for Corium International Inc Raised by Cantor Fitzgerald (CORI)|
www.americanbankingnews.com - February 14 at 11:24 AM
|Corium International (CORI) PT Set at $14.00 by HC Wainwright|
www.americanbankingnews.com - February 10 at 4:44 PM
|Corium Reports First Quarter Fiscal 2018 Financial Results and Corporate Highlights|
finance.yahoo.com - February 8 at 4:42 PM
|Corium International Inc (CORI) Expected to Announce Earnings of -$0.43 Per Share|
www.americanbankingnews.com - February 7 at 9:52 AM
|Corium to Present at Upcoming Healthcare Investor Conferences|
finance.yahoo.com - February 6 at 8:48 AM
|Tetraphase Pharmaceuticals (TTPH) vs. Corium International (CORI) Financial Analysis|
www.americanbankingnews.com - February 5 at 1:39 PM
|Corium International (CORI) Lowered to "Hold" at BidaskClub|
www.americanbankingnews.com - February 3 at 11:58 AM
|Corium to Report First Quarter Fiscal 2018 Financial Results on Thursday, February 8, 2018|
finance.yahoo.com - February 1 at 4:46 PM
|Head to Head Review: Corium International (CORI) and Novo Nordisk A/S (NVO)|
www.americanbankingnews.com - January 31 at 9:12 PM
|3 Hot Insider Biotech Stocks You Need to Know|
www.nasdaq.com - January 29 at 8:54 AM
|Corium International Inc (CORI) Receives Average Rating of "Buy" from Brokerages|
www.americanbankingnews.com - January 26 at 5:38 PM
|Corium International (CORI) Raised to Hold at Zacks Investment Research|
www.americanbankingnews.com - January 22 at 9:18 PM
|Zacks: Brokerages Anticipate Corium International Inc (CORI) to Announce -$0.43 Earnings Per Share|
www.americanbankingnews.com - January 21 at 11:24 AM
|Corium International Inc (CORI) Major Shareholder Perceptive Advisors Llc Acquires 50,350 Shares|
www.americanbankingnews.com - January 18 at 7:00 PM
|Corium International Inc (CORI) Major Shareholder Life Sciences Maste Perceptive Purchases 510,000 Shares|
www.americanbankingnews.com - January 18 at 6:34 PM
|FY2018 EPS Estimates for Corium International Inc (CORI) Cut by Cantor Fitzgerald|
www.americanbankingnews.com - January 18 at 4:36 PM
|Corium International Inc (CORI) Expected to Post Quarterly Sales of $7.48 Million|
www.americanbankingnews.com - January 6 at 4:14 AM
|Corium International Inc (CORI) Expected to Post FY2019 Earnings of ($0.94) Per Share|
www.americanbankingnews.com - January 4 at 10:42 PM
|Head-To-Head Analysis: Corium International (CORI) versus Its Peers|
www.americanbankingnews.com - January 3 at 5:34 PM
|Critical Comparison: Corium International (CORI) & Its Competitors|
www.americanbankingnews.com - January 2 at 5:12 PM
|Corium International Inc (CORI) Given Consensus Rating of "Buy" by Analysts|
www.americanbankingnews.com - January 1 at 5:38 PM
|Corium International, Inc. :CORI-US: Earnings Analysis: Q4, 2017 By the Numbers : January 1, 2018|
finance.yahoo.com - January 1 at 9:47 AM
|Critical Contrast: Corium International (CORI) & Its Rivals|
www.americanbankingnews.com - January 1 at 3:28 AM
|Corium International (CORI) versus Its Rivals Head to Head Analysis|
www.americanbankingnews.com - January 1 at 1:30 AM
|Equities Analysts Offer Predictions for Corium International Inc's FY2018 Earnings (CORI)|
www.americanbankingnews.com - December 30 at 9:32 PM
|Corium International (CORI) Downgraded to Sell at Zacks Investment Research|
www.americanbankingnews.com - December 29 at 9:26 PM
|Free Research Report as Corium's Revenue Grew 19.2%|
finance.yahoo.com - December 29 at 4:56 PM
|Corium International Inc (CORI) Files 10-K for the Fiscal Year Ended on September 30, 2017|
finance.yahoo.com - December 29 at 9:06 AM
|Head to Head Review: Corium International (CORI) versus Its Rivals|
www.americanbankingnews.com - December 28 at 7:34 PM
|What Should We Expect From Corium International Inc’s (NASDAQ:CORI) Earnings In Next 12 Months?|
finance.yahoo.com - December 27 at 5:59 PM
|Analyst Remains Confident In Corium Despite Partner's Bad FDA News|
feeds.benzinga.com - December 27 at 12:41 PM
|Needham & Company LLC Lowers Corium International (CORI) Price Target to $14.00|
www.americanbankingnews.com - December 26 at 8:34 AM
|Corium International, Inc. breached its 50 day moving average in a Bearish Manner : CORI-US : December 25, 2017|
finance.yahoo.com - December 25 at 6:42 PM
|Critical Review: Corium International (CORI) and The Competition|
www.americanbankingnews.com - December 24 at 5:15 AM
|Financial Contrast: Corium International (CORI) & Its Peers|
www.americanbankingnews.com - December 23 at 11:40 AM
Corium International (NASDAQ:CORI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Corium International (NASDAQ:CORI) Income Statement, Balance Sheet and Cash Flow Statement
Corium International (NASDAQ CORI) Stock Chart for Saturday, March, 17, 2018